By Ludwig Burger FRANKFURT, March 10 (Reuters) - The two co-founders and leading executives of Germany's BioNTech will leave the COVID-19 vaccine maker by the end of 2026 to ‌start again with a new ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — The co-founders of the ...

(Bloomberg) -- BioNTech SE’s founders will leave the company to start a new biotech focused on messenger RNA, the technology behind their blockbuster Covid-19 vaccine, dashing investors’ confidence in ...

BioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA candidates BioNTech co-founders Ugur Sahin and Özlem Türeci will ...

BioNTech aims to have multiple commercialised cancer drugs by 2030 as the company continues its pivot away from Covid-19 vaccines. Speaking at the J.P. Morgan Healthcare Conference in San Francisco, ...

BioNTech's stock fell 19% after its co-founders said they are leaving to start a new mRNA-based company Ugur Sahin and Özlem Türeci, the co-founders of BioNTech, were given the Axel Springer Award in ...

BioNTech (NASDAQ: BNTX) swung to a Q4 loss and guided for “lower-than-expected” full-year revenue on Tuesday. But the stock crashed more than 20%, mostly because its cofounders, Ugur Sahin (CEO) and ...

CEO Ugur Sahin highlighted that BioNTech maintained its leadership in the COVID vaccine market, launching a variant-adapted vaccine in partnership with Pfizer, now distributed in over 180 countries ...

BioNTech’s co-founders, the husband-and-wife team who helped bring the first Covid-19 vaccine to the market during the depths of the pandemic, are leaving the company to form a new startup. Their ...